Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a diagnosis of migraine, with or without aura, as determined by the study investigator and in consideration of International Headache Society International Classification of Headache Disorders - 3rd edition guidelines (ICHD-3 2018)
Have a frequency of less than 15 monthly headache days of which up to 14 can be migraine headache days.
Participants can be on no more than 1 other migraine preventive treatment (except for tricyclic antidepressants and verapamil which are not allowed) as long as: that participant has had a stable dose of the oral migraine preventive treatment for a minimum of 2 months or participants have received onabotulinumtoxinA for a minimum of 2 cycles prior to screening
You may not be if
Participants with a history of gastric bezoars, swallowing disorders, severe dysphagia to food or pills, suspected or known strictures, fistulas, or physiological/mechanical GI obstruction
History of any abdominal surgery within the past 3 months or GI surgery with the exception of cholecystectomy, appendectomy, or Nissen fundoplication
History of irritable bowel syndrome (IBS), chronic constipation, Crohn's disease, celiac disease, ulcerative colitis, or diverticulitis
Participants with type 1 or type 2 diabetes
Participants with cardiac pacemakers or other implanted or portable electromechanical device
Participants with a body mass index of ≥40 kilograms per square meter (kg/m²)
Women who are pregnant or nursing
Participants currently on mAb CGRP antagonists or have received a mAb CGRP antagonist within the past 6 months prior to visit 1
Participants who have received an oral CGRP antagonist (gepant) in the last 14 days prior to Visit 1
